Skip to content

Quality of life improvement with vitamin D supplementation in allergic rhinitis patients.

Effect of vitamin D supplementation on quality of life of patients with perennial Allergic Rhinitis: A Randomized Controlled Trial. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/09/073462
Enrollment
90
Registered
2024-09-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J30- Vasomotor and allergic rhinitis

Interventions

Intervention1: To evaluate the effect of vitamin D supplementation on quality of life of patients with perennial allergic rhinitis.: • To evaluate quality of life in perennial allergic rhinitis patien

Sponsors

Geetanjali Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. Perennial Allergic Rhinitis patients with serum 25 (OH)-Vitamin-D3 levels less than 20 ng/ml. ii. Patients who will give informed consent for participation in the study.

Exclusion criteria

Exclusion criteria: i. Associated Nasal co-morbidities like Nasal Polyposis, Sinusitis, Deviated Nasal Septum, Autoimmune disease of nose. ii. Associated Systemic co-morbidities affecting vitamin D levels like Juvenile Idiopathic Arthritis, Rickets, Cystic Fibrosis, Ulcerative Colitis, Crohn’s disease, Celiac disease, Thyroid dysfunction. iii. Individuals who had received medications including corticosteroids, barbiturates, bisphosphonates, omega-3 fatty acids, anti-epileptics and vitamin D. iv. Pregnant and breastfeeding women.

Design outcomes

Primary

MeasureTime frame
Improvement in TEC levels, TNSS score and RCAT score with Vitamin D supplementationTimepoint: Baseline(at 0 weeks), 4 weeks and 8 weeks

Secondary

MeasureTime frame
Better understanding of the relation between serum vitamin D levels & symptom severity of perennial allergic rhinitis.Timepoint: Baseline(at 0 weeks), 4 weeks & 8 weeks

Countries

India

Contacts

Public ContactArindam Malik

Geetanjali Medical College and Hospital

drnitinz@gmail.com9610089189

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026